Gilead Sciences Inc. logo

Gilead Sciences Inc. (GILD)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
156. 19
-1.18
-0.7498%
$
187.44B Market Cap
17.2 P/E Ratio
0.42% Div Yield
7.77M Volume
6.22 Eps
$ 157.37
Previous Close
Add Transaction
Day Range
155.62 157.58
Year Range
114.02 160.51
Want to track GILD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts

Gilead Sciences (GILD) Advances But Underperforms Market: Key Facts

Gilead Sciences (GILD) reached $141.54 at the closing of the latest trading day, reflecting a +1.97% change compared to its last close.

Zacks | 6 months ago
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 6 months ago
Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript

Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript

Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript

Seekingalpha | 6 months ago
Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion

Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in contingency payments.

Barrons | 6 months ago
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline.

Wsj | 6 months ago
Gilead to acquire Tubulis GmbH for up to $5 billion

Gilead to acquire Tubulis GmbH for up to $5 billion

Gilead said ​on Tuesday ‌it would acquire ​private ​Germany-based Tubulis GmbH ⁠for ​up ​to $5 billion, boosting the ​U.S. ​drugmaker's pipeline with ‌a ⁠lucrative class of experimental ​cancer ​drugs ⁠referred to ​as "guided ​missiles".

Reuters | 6 months ago
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 6 months ago
Markets Haven't Changed. These 2 Cheap Dividends Still Rule

Markets Haven't Changed. These 2 Cheap Dividends Still Rule

Fear is up, markets are down—and we contrarians know that times like these are when we go shopping for cheap dividends.

Forbes | 6 months ago
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Gilead Sciences (GILD) closed at $139.37, marking a +2.22% move from the previous day.

Zacks | 6 months ago
Gilead Sciences, Inc. (GILD) M&A Call Transcript

Gilead Sciences, Inc. (GILD) M&A Call Transcript

Gilead Sciences, Inc. (GILD) M&A Call Transcript

Seekingalpha | 6 months ago
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead Sciences (GILD) closed the most recent trading day at $134.25, moving 1.92% from the previous trading session.

Zacks | 6 months ago
Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 6 months ago
Loading...
Load More